phrykt

Nasus Pharma Ltd (NSRX): who owns it and who trades it

As of Nov 16, 2026, NSRX insiders reported 3 purchases worth $61.8K in the last 12 months. The largest buyer was Dan Benjamin Teleman (CEO), with $61.8K. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Nasus Pharma

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, NSRX insiders reported $61.8K of open-market purchases and $0 of sales.

Purchases, 12 months
$61.8K
3 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Jun 17, 2026
Filed Jun 22, 2026

Purchases and sales by month

$30.6K$30.6KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jun 17, 2026Dan Benjamin TelemanCEOPurchase6,550$3.10$20.3KForm 4
Apr 22, 2026Dan Benjamin TelemanCEOPurchase2,900$3.76$10.9KForm 4
Mar 31, 2026Dan Benjamin TelemanCEOPurchase15,000$2.04$30.6KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Dan Benjamin TelemanChief Executive Officer, Director$61.8K–Jun 17, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

NSRX short interest

71,005 NSRX shares are sold short. Over the last 12 reports the number of shares short went down 54%.

As of Oct 30, 2026, 71,005 NSRX shares were sold short, down 11.7% from the report before. At the average daily volume of 19,443 shares, buying them all back would take about 3.6 trading days (days to cover).

Shares short, % of all shares

1.89%May 15Jul 152.01%

Days to cover

3.6May 15Oct 3017.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202671,005–-12%19,4433.6
Oct 15, 202680,432–+3%17,1634.7
Sep 30, 202678,238–-3%27,2462.9
Sep 15, 202680,533–-8%10,1168.0
Aug 31, 202687,272–-40%14,7835.9
Aug 14, 2026144,506–-10%17,6708.2
Jul 31, 2026160,076–-6%10,55915.2
Jul 15, 2026170,6671.89%-1%14,45411.8
Jun 30, 2026172,1401.91%-3%25,0016.9
Jun 15, 2026177,4661.97%+3%42,9084.1
May 29, 2026172,4841.91%+11%55,7233.1
May 15, 2026155,0321.72%+40%72,4472.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Nasus Pharma financials

Famous investors that hold NSRX

1 of the 50 well-known investors we track reported holding NSRX in their latest 13F filing. The largest position is Jim Simons's, worth $53.9K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 202614,600$53.9K0.0%+20%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named NSRX in the last 120 days.

FiledHolderFormStake
Nov 16, 2026BALYASNY ASSET MANAGEMENT L.P.13G/A10.0%
Nov 16, 2026BALYASNY ASSET MANAGEMENT L.P.13G/A10.0%

Questions about Nasus Pharma Ltd (NSRX) stock

Are NSRX insiders buying or selling?

In the last 12 months, NSRX insiders reported 3 open-market purchases worth $61.8K and no sales. The latest trade was on Jun 17, 2026. See every trade.

What is the short interest in NSRX?

As of Oct 30, 2026, 71,005 NSRX shares were sold short, down 11.7% from the report before. At the average daily volume of 19,443 shares, buying them all back would take about 3.6 trading days (days to cover). See the history.

Which famous investors hold NSRX?

1 of the 50 well-known investors we track reported NSRX in their latest 13F filing, including Jim Simons. The largest position is worth $53.9K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.